The Double-Edged Sword of Biological Explanations in Mental Health
Psychopharmacology and Psychiatry Updates
Release Date: 12/02/2024
Psychopharmacology and Psychiatry Updates
In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore a groundbreaking Danish registry study that challenges common beliefs about long-term benzodiazepine use and dose escalation patterns. Are our concerns about inevitable tolerance and dependence justified? The study's findings might surprise you and reshape prescribing practices. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore the side effects and safety considerations of Transcranial Magnetic Stimulation (TMS) therapy in psychiatry. Did you know that despite common concerns, fewer than 2% of patients discontinue TMS due to discomfort? We'll discuss everything from common side effects to practical management strategies. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.
info_outlinePsychopharmacology and Psychiatry Updates
In this episode, we explore the crucial interaction between SSRIs and oral anticoagulants, examining a groundbreaking 23-year study of over 330,000 patients. Does combining these medications significantly increase bleeding risk, and if so, how can we safely manage patients who need both treatments? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.
info_outlineIn this episode, we explore the unexpected consequences of promoting a purely biological view of mental illness. How does framing mental health conditions as solely biological affect stigma, patient outcomes, and physician empathy? We delve into the complex interplay between biological and psychosocial factors in mental health treatment.
Faculty: David Mintz, M.D.
Host: Richard Seeber, M.D.